TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT05253937

Intervention type: DRUG
Intervention: Epinephrin
Description: The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.

Intervention type: DRUG
Intervention: Epinephrin
Description: The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.

Intervention type: DRUG
Intervention: Epinephrin
Description: The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
Study: NCT03831178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
Study: NCT02225704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 and enzalutamide
Study: NCT04069949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib; toripalimab
Description: Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
Study: NCT01663766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milatuzumab
Description: Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
Study: NCT00005945

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT04082637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy
Description: A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
Study: NCT00005945

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT00477256

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
Study: NCT03788967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr tablets administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Antibiotic Therapy for cUTI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dummy Infusion
Description: Dummy intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dummy tablets
Description: Dummy tablets orally.
Study: NCT01685203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study: NCT00477256

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
Study: NCT00458211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
Study: NCT01685203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study: NCT04285372

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Side branch protection/ballooning
Description: Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No side branch protection/ballooning
Description: No intervention on the side branch
Study: NCT01202760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2127399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02911519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Group Psychoeducation
Description: First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
Study: NCT00399568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Intravenous acetaminophen 1 g/100 mL
Study: NCT03647176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare polypectomy
Description: cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
Study: NCT00399568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo 100 mL solution
Description: IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
Study: NCT01634113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium-bromide
Description: IMP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium-bromide
Description: IMP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching tiotropium
Study: NCT02979444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Groups
Description: The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Groups
Description: The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood.
Study: NCT03432572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridium
Description: a urine discoloration agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: a urine discoloration agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: active placebo not known to cause urine discoloration
Study: NCT01033604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glyaderm and split skin graft
Description: Full thickness defects treated with Glyaderm and split skin graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft alone.
Description: Full thickness defects treated with split skin graft alone.
Study: NCT01993667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Acetazolamide
Description: Administration of low dose acetazolamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Dose Acetazolamide
Description: Administration of normal dose acetazolamide
Study: NCT01807767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus, Myfortic and Tacrolimus
Description: Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: Myfortic and Tacrolimus
Description: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
Study: NCT01318668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccination with Nicvax
Description: 5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
Study: NCT02552667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1102+HGP0711Placebo
Description: Coadministration of HCP1102 with HGP0711 Placebo for 4-week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1102Placebo+HGP0711
Description: Coadministration of HCP1102 Placebo with HGP0711 for 4-week
Study: NCT00600275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT226
Study: NCT02424500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: d-Nav
Description: Insulin dosage is adjusted as required

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Glucose Monitoring System
Description: Insulin dosage is adjusted as required
Study: NCT01061723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT01680354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ReLEx

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Study: NCT04354948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain (hypertonic saline)
Description: A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No pain (Hypotonic saline)
Description: A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
Study: NCT02476032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prof applied oxalate
Description: Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self applied oxalate
Description: Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
Study: NCT03621189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study: NCT03483831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
Study: NCT04822311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Investigate the effects of an exercise intervention on retired APF players
Description: Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
Study: NCT02468141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJDBT
Description: Sipjeondaebo-tang

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00580021

Intervention type: OTHER
Intervention: Genotyping
Description: Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
Study: NCT03126279

Intervention type: PROCEDURE
Intervention: Total Knee Replacement Surgery
Description: All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
Study: NCT01569087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: empegfilrastim
Description: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: empegfilrastim
Description: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
Study: NCT02476032

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Prof applied placebo
Description: Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.